{"id":9733,"date":"2020-04-10T17:51:45","date_gmt":"2020-04-10T08:51:45","guid":{"rendered":"https:\/\/dev.rftcjapan.org\/pink-article\/am-i-eligible-for-abemaciclib-2\/"},"modified":"2020-04-10T17:51:45","modified_gmt":"2020-04-10T08:51:45","slug":"am-i-eligible-for-abemaciclib","status":"publish","type":"post","link":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","title":{"rendered":"Am I eligible for abemaciclib?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">PiNK 2020 Spring issue<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>\u3010Your Questions Answered\u3011Breast Cancer Care\u2019s experts answer your questions about breast cancer and its treatments.<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Q: I have secondary breast cancer in the lung, and have heard about a drug called abemaciclib. Can I have this?<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A: Abemaciclib is a targeted therapy used to treat secondary breast cancer. It belongs to a group of drugs known as CDK 4\/6 inhibitors. Other drugs in the same group are palbococlib and ribociclib.These drugs can be given to people who have secondary breast cancer that that is both oestrogen receptor positive (ER+) and HER2 negative.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Abemaciclib has been approved for use on the NHS and can be given as the first treatment for secondary breast cancer alongside an aromatase inhibitor, such as letrozole. It can also be given in combination with a drug called fulvestrant if you have had hormone therapy for secondary breast cancer in the past. Your specialist team can tell you if abemaciclib is an option in your situation.<\/strong><\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>PiNK 2020 Spring issue \u3010Your Questions Answered\u3011Breast Cancer Care\u2019s experts answer your questions about breast cancer and its treatments. Q: I have secondary breast cancer in the lung, and have heard about a drug called abemaciclib. Can I have this? A: Abemaciclib is a targeted therapy used to treat secondary breast cancer. It belongs to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10287,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[324,80,85,171,267],"class_list":["post-9733","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pink-article","tag-abemaciclib","tag-breast-cancer-ja","tag-pink","tag-q-a","tag-your-questions-answered-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Am I eligible for abemaciclib? - RFTC Japan<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Am I eligible for abemaciclib? - RFTC Japan\" \/>\n<meta property=\"og:description\" content=\"PiNK 2020 Spring issue \u3010Your Questions Answered\u3011Breast Cancer Care\u2019s experts answer your questions about breast cancer and its treatments. Q: I have secondary breast cancer in the lung, and have heard about a drug called abemaciclib. Can I have this? A: Abemaciclib is a targeted therapy used to treat secondary breast cancer. It belongs to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/\" \/>\n<meta property=\"og:site_name\" content=\"RFTC Japan\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-10T08:51:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/PiNK-2020-SPRING-03.002-1200x675.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"michael\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"michael\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\"},\"author\":{\"name\":\"michael\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#\\\/schema\\\/person\\\/5f9c8ca2f816ff93dec0cfdff2303f89\"},\"headline\":\"Am I eligible for abemaciclib?\",\"datePublished\":\"2020-04-10T08:51:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\"},\"wordCount\":169,\"image\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/PiNK-2020-SPRING-03.002.jpeg\",\"keywords\":[\"abemaciclib\",\"breast-cancer-ja\",\"pink\",\"q-a\",\"your-questions-answered-2\"],\"articleSection\":[\"PiNK\u8a18\u4e8b\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\",\"url\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\",\"name\":\"Am I eligible for abemaciclib? - RFTC Japan\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/PiNK-2020-SPRING-03.002.jpeg\",\"datePublished\":\"2020-04-10T08:51:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#\\\/schema\\\/person\\\/5f9c8ca2f816ff93dec0cfdff2303f89\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#primaryimage\",\"url\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/PiNK-2020-SPRING-03.002.jpeg\",\"contentUrl\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/PiNK-2020-SPRING-03.002.jpeg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Am I eligible for abemaciclib?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/\",\"name\":\"RFTC Japan\",\"description\":\"Japan&#039;s Leading Breast Cancer Foundation\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#\\\/schema\\\/person\\\/5f9c8ca2f816ff93dec0cfdff2303f89\",\"name\":\"michael\",\"sameAs\":[\"https:\\\/\\\/rftcjapan.org\\\/wpdata\"],\"url\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/author\\\/michael\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Am I eligible for abemaciclib? - RFTC Japan","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","og_locale":"en_US","og_type":"article","og_title":"Am I eligible for abemaciclib? - RFTC Japan","og_description":"PiNK 2020 Spring issue \u3010Your Questions Answered\u3011Breast Cancer Care\u2019s experts answer your questions about breast cancer and its treatments. Q: I have secondary breast cancer in the lung, and have heard about a drug called abemaciclib. Can I have this? A: Abemaciclib is a targeted therapy used to treat secondary breast cancer. It belongs to [&hellip;]","og_url":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","og_site_name":"RFTC Japan","article_published_time":"2020-04-10T08:51:45+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/PiNK-2020-SPRING-03.002-1200x675.jpeg","type":"image\/jpeg"}],"author":"michael","twitter_card":"summary_large_image","twitter_misc":{"Written by":"michael","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#article","isPartOf":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/"},"author":{"name":"michael","@id":"https:\/\/rftcjapan.org\/en\/#\/schema\/person\/5f9c8ca2f816ff93dec0cfdff2303f89"},"headline":"Am I eligible for abemaciclib?","datePublished":"2020-04-10T08:51:45+00:00","mainEntityOfPage":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/"},"wordCount":169,"image":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#primaryimage"},"thumbnailUrl":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/PiNK-2020-SPRING-03.002.jpeg","keywords":["abemaciclib","breast-cancer-ja","pink","q-a","your-questions-answered-2"],"articleSection":["PiNK\u8a18\u4e8b"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","url":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","name":"Am I eligible for abemaciclib? - RFTC Japan","isPartOf":{"@id":"https:\/\/rftcjapan.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#primaryimage"},"image":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#primaryimage"},"thumbnailUrl":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/PiNK-2020-SPRING-03.002.jpeg","datePublished":"2020-04-10T08:51:45+00:00","author":{"@id":"https:\/\/rftcjapan.org\/en\/#\/schema\/person\/5f9c8ca2f816ff93dec0cfdff2303f89"},"breadcrumb":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#primaryimage","url":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/PiNK-2020-SPRING-03.002.jpeg","contentUrl":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/PiNK-2020-SPRING-03.002.jpeg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rftcjapan.org\/en\/"},{"@type":"ListItem","position":2,"name":"Am I eligible for abemaciclib?"}]},{"@type":"WebSite","@id":"https:\/\/rftcjapan.org\/en\/#website","url":"https:\/\/rftcjapan.org\/en\/","name":"RFTC Japan","description":"Japan&#039;s Leading Breast Cancer Foundation","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rftcjapan.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/rftcjapan.org\/en\/#\/schema\/person\/5f9c8ca2f816ff93dec0cfdff2303f89","name":"michael","sameAs":["https:\/\/rftcjapan.org\/wpdata"],"url":"https:\/\/rftcjapan.org\/en\/author\/michael\/"}]}},"_links":{"self":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts\/9733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/comments?post=9733"}],"version-history":[{"count":0,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts\/9733\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/media\/10287"}],"wp:attachment":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/media?parent=9733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/categories?post=9733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/tags?post=9733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}